Recombinant CTLA4 anticorps

N° du produit ABIN7072438

Cet anticorps Hamster Monoclonal détecte spécifiquement CTLA4 dans FACS, WB, ELISA, Neut et ProA. Il présente une réactivité envers Souris.

Aperçu rapide pour Recombinant CTLA4 anticorps (ABIN7072438)

Antigène: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Type d'anticorp: Recombinant Antibody

Reactivité: Souris

Hôte: Hamster

Clonalité: Monoclonal

Conjugué: Cet anticorp CTLA4 est non-conjugé

Application: Flow Cytometry (FACS), Western Blotting (WB), ELISA, Neutralization (Neut), Proliferation Assay (ProA)

Clone: 9H10

Détail du produit anti-CTLA4 anticorps

Fonction: Anti-CTLA-4 [9H10], Hamster (Armenian) IgG, kappa

Specificité: This antibody is specific for murine CTLA-4, an inhibitory receptor that acts as the primary negative regulator of T-cell responses. CTLA-4 is expressed predominantly by activated T cells, with significantly higher levels of expression on CD8+ T cells than CD4+ T cells.

Attributs du produit:

Original Species of Ab: Hamster, Armenian

Original Format of Ab: IgG2

Purification: Protein A affinity purified

Immunogène: This antibody was raised by immunising Syrian hamsters with Staphylococcus A bacteria coated in CTLA-4, isolating B cells from the immunised hamsters and fusing these with the P3X3.Ag8.653 myeloma line to produce stable hybridomas.

Isotype: IgG kappa

Information d'application

Indications d'application: CTLA-4 is upregulated on T cells following their activation, and acts as a negative regulator of T cell responses, CTLA-4 binds to the B7 Molecules CD80 and 86, resulting in the delivery of an inhibitory signal, and consequent downregulation of T cell-mediated immunity. Administration of 9H10 blocks the interaction between CTLA-4 on the T cell surface and CD80 and CD86. This promotes the activation of effector T cells and stimulates the immune response raised against weak antigens, including tumour antigens. While this antibody alone does not enhance T cell proliferation, it does significantly increase T cell proliferation when administered together with anti-CD28 (clone 37.51) (Krummel & Allison, 1995), anti-OX40 and anti-GITR (Houot & Levy, 2009). Blocking CTLA-4 induces T cell anti-tumour immunity in animal models, both by suppressing regulatory T cell activity and directly promoting CD8+ T cell effector function (Peggs et al, 2009). In transgenic murine models of prostate cancer, the use of a CTLA-4 blockade in conjunction with an irradiated tumour cell vaccine stimulates an immune response against primary tumours, and results in a significant reduction in tumour incidence (Hurwitz et al, 2000). Similarly, in murine melanoma models, CTLA-4 blockage, in combination with CD40 stimulation and adenoviral vaccination, can elicit complete regression (Sorensen et al, 2010). In murine models of pancreatic ductal adenocarcinoma, 9H10 has also been shown to induce T cell-dependent tumour regressions (Vonderheide et al, 2015). Priming the T cell response with CD40 mAbs or chemotherapy reversed the resistance to 9H10 and RMP1-14 observed in well-established tumours. Additionally, this antibody has been used to detect CTLA-4 using ELISA (Krummel & Allison, 1995) and to stain CTLA-4-expressing cells (Deeths et al, 1999).

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Détails sur CTLA4

Antigène: CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))

Autre désignation: CTLA-4

Sujet: CD152, CTLA4, cytotoxic T-lymphocyte-associated antigen 4, Cytotoxic T-lymphocyte protein 4,

UniProt: P09793

Pathways: Cancer Immune Checkpoints